House of Lords Business
Show full summary

The Countess of Mar to ask Her Majesty's Government, further to the Written Answer by Earl Howe on 22 November (HL3229), what assessment they have made of the conclusions of the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency in 2014 that: “There is enough evidence … supporting a causal relationship between mefloquine and the occurrence of long lasting and even persistent neuropsychiatric side effects” and a “strong suspicion” that mefloquine can cause “permanent brain damage”.  HL3532

Question HL3532: tabled on 23 November 2017 and due for answer by 7 December 2017

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

The Countess of Mar to ask Her Majesty's Government, further to the Written Answer by Earl Howe on 22 November (HL3229), what assessment they have made of the conclusions of the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency in 2014 that: “There is enough evidence … supporting a causal relationship between mefloquine and the occurrence of long lasting and even persistent neuropsychiatric side effects” and a “strong suspicion” that mefloquine can cause “permanent brain damage”.  HL3532
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

The Countess of Mar
Crossbench
Excepted Hereditary